Oxford BioMedica - Announcements

News / Announcements 2004

Date	Article

16 Dec 2004	Oxford BioMedica Publishes Preclinical Efficacy Results with its Product Candidate SMN1-G for Spinal Muscular Atrophy

13 Dec 2004	Oxford BioMedica Licenses Retroviral Ex Vivo Gene Delivery Technology to MolMed SpA

29 Oct 2004	Oxford BioMedica and ARIUS Research Extend Collaboration on Novel Cancer Targets

17 Sept 2004	Oxford BioMedica Signs License Agreement with Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute

1 Sept 2004	Oxford BioMedica Announces Positive Interim Phase II Results with Trovax in Colorectal Cancer

1 Sept 2004	Oxford BioMedica Plc Interim Results for the Six Months Ended 30 June 2004

24 Aug 2004	Interim Results : Web Cast Notification Wednesday 1 September 2004

18 Aug 2004	Appointment of Broker

5 July 2004	Oxford BioMedica Licenses LentiVector^® Technology to Viragen for Avian Transgenics Biomanufacturing

30 June 2004	Notice of Interim Results for the Six Months Ended 30 June 2004

21 June 2004	Oxford BioMedica Publication – LentiVector^® Gene Delivery System Results in High Success Rate in Avian Transgenics Program

17 June 2004	Oxford BioMedica – Innurex^® Programme

7 June 2004	Oxford BioMedica Acquires Chiron Patents and Issues Shares to Chiron

2 June 2004	Oxford BioMedica’s Innurex^® Product Restores Limb Function in a Preclinical Model of Avulsion Injury

27 May 2004	UK Scientists Pioneer Novel Treatment for Motor Neuron Disease

12 May 2004	Oxford BioMedica Plc Appointment of Senior Independent Director

29 Apr 2004	Oxford BioMedica Gains FDA Approval for a Phase II Trial of Trovax^® in Renal Cancer

20 Apr 2004	Oxford BioMedica Annual General Meeting 2004

29 Mar 2004	Oxford BioMedica Awarded £0.5 Million from the UK Department of Health Gene Therapy Research Programme

16 Mar 2004	Notice of Annual General Meeting

3 Mar 2004	Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2003

5 Feb 2004	Oxford BioMedica Signs LentiVector^® Licensing Agreement with Merck & Co

21 Jan 2004	Notice of Preliminary Results

16 Jan 2004	Oxford BioMedica Announces that Cancer Research UK has Received Approval to Start a Phase II Trial with TroVax^® in Colorectal Cancer

Website by College Hill - Life Sciences

2008

Archive

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997